Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Risk Adapted Antifungal Strategy in Allogeneic Stem Cell Transplantation. Should We Change the Current Guidelines?

Lucrecia Yanez San Segundo, MD PhD, Noemi Fernandez Escalada, MD, Arancha Bermúdez, MD, Guillermo Martín Sánchez, MD, Sara García Avila, MD, Mónica López Duarte, MD, Mercedes Colorado, MD, Iñigo Romon, MD PhD, Carlos Richard, MD, Enrique M. Ocio, MD PhD

Blood (2019) 134 (Supplement_1): 5655.

https://doi.org/10.1182/blood-2019-130731

Published: 2019

Journal Articles

The Poor Prognosis of High Cytogenetics Abnormalities in Elderly Patients Might be Overcome with an Optimized Total Therapy Approach Including Proteasome Inhibitors, Imid's Compounds and Alkylators

Blood (2016) 128 (22): 5688.

https://doi.org/10.1182/blood.V128.22.5688.5688

Published: 2016

Journal Articles

Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

Shaji Kumar, MD, Meletios A Dimopoulos, Efstathios Kastritis, MD, Evangelos Terpos, Hareth Nahi, Hartmut Goldschmidt, MD, Jens Hillengass, MD, Xavier Leleu, Meral Beksac, MD, Melissa Alsina, MD, Albert Oriol, MD, Michele Cavo, MD, Enrique M. Ocio, MD PhD, Maria Victoria Mateos, Elizabeth K. O'Donnell, MD, Ravi Vij, MD MBA, Henk M. Lokhorst, MD PhD, Niels W.C.J. van de Donk, MD PhD, Chang-Ki Min, Tomer Mark, MD MSc, Ingemar Turesson, MD, PhD, Markus Hansson, MD, Heinz Ludwig, Sundar Jagannath, MD, Michel Delforge, MD PhD, Charalampia Kyriakou, MD PhD, Parameswaran Hari, MBBS, MD MRCP, Ulf-Henrik Mellqvist, MD PhD, Saad Z Usmani, MD FACP, Dominik Dytfeld, MD PhD, Ashraf Z Badros, MD, Philippe Moreau, Kihyun Kim, MD PhD, Paula Rodriguez Otero, MD, Jae Hoon Lee, MD, Chaim Shustik, MD, Daniel Waller, PhD, Wee Joo Chng, MD PhD, Shuji Ozaki, MD PhD, Je-Jung Lee, Javier de la Rubia, Hyeon Seok Eom, MD PhD, Laura Rosinol, MD PhD, Juan José Lahuerta, MD PhD, Anna Sureda, MD PhD, Jin Seok Kim, MD PhD, Brian G.M. Durie, MD

Blood (2016) 128 (22): 4414.

https://doi.org/10.1182/blood.V128.22.4414.4414

Published: 2016

Journal Articles

Safety and Efficacy of Filanesib in Combination with Pomalidomide and Dexamethasone in Refractory MM Patients. Phase Ib/II Pomdefil Clinical Trial Conducted By the Spanish MM Group

Enrique M. Ocio, MD PhD, Cristina Motlló, MD, Paula Rodriguez-Otero, MD PhD, Joaquín Martínez-López, MD PhD, Javier De La Rubia, Mieke Ptaszynski, Brian Tunquist, Ramon Garcia-Sanz, MD PhD, Albert Oriol, Juan José Lahuerta, MD PhD, Jesús San-Miguel, MD PhD, Maria-Victoria Mateos, MD PhD

Blood (2016) 128 (22): 4503.

https://doi.org/10.1182/blood.V128.22.4503.4503

Published: 2016

Journal Articles

Ultra-Deep Targeted Sequencing Does Not Identify MM Patients with Different Prognosis: Results from a Randomized Phase II Clinical Trial

Blood (2016) 128 (22): 2078.

https://doi.org/10.1182/blood.V128.22.2078.2078

Published: 2016

Journal Articles

Whole-Exome Sequencing of Waldenström Macroglobulinemia Transformation into Aggressive Lymphoma

Sara Alonso, MD PhD, Cristina Jiménez, BSc, Miguel Alcoceba, BSc, PhD, María García-Álvarez, BSc, Isabel Prieto-Conde, BSc, M. Carmen Chillon, BSc, PhD, M. Eugenia A. Sarasquete, BSc, PhD, Noemi Puig, MD PhD, Maria-Victoria Mateos, MD PhD, Enrique M. Ocio, MD PhD, Marcos González, MD PhD, Ramon Garcia-Sanz, MD PhD

Blood (2016) 128 (22): 4101.

https://doi.org/10.1182/blood.V128.22.4101.4101

Published: 2016

Journal Articles

Prognostic Value of Immune Profiling Multiple Myeloma Patients during Minimal Residual Disease Monitoring in the Pethema/GEM2010MAS65 Study

Paula Arana, Bruno Paiva, PhD, Noemi Puig, MD PhD, Teresa Cedena, Lourdes Cordon, Maria Belen Vidriales, MD PhD, Joaquin Martinez-López, MDPhD, Enrique M. Ocio, MD PhD, Miguel T Hernandez, Ana Isabel Teruel, MD, Mercedes Gironella, M Asuncion Echeveste, Laura Rosiñol, MDPhD, Rafael Martinez, MDPhD, Albert Oriol, MDPhD, Joan Blade, MDPhD, Juan Jose Lahuerta, Maria-Victoria Mateos, Jesus San Miguel, MDPhD

Blood (2015) 126 (23): 721.

https://doi.org/10.1182/blood.V126.23.721.721

Published: 2015

Journal Articles

Comparison Between First-Generation 4-Color Vs. Second-Generation 8-Color Multiparameter Flow Cytometry (MFC) to Monitor Minimal Residual Disease (MRD) in Multiple Myeloma (MM)

Blood (2015) 126 (23): 2963.

https://doi.org/10.1182/blood.V126.23.2963.2963

Published: 2015

Journal Articles

The Relevance of Minimal Residual Disease (MRD) Monitoring in Elderly Multiple Myeloma (MM) Patients

Blood (2015) 126 (23): 4181.

https://doi.org/10.1182/blood.V126.23.4181.4181

Published: 2015

Journal Articles

An Updated Analysis of the Stratus Trial (MM-010): Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Meletios A. Dimopoulos, Antonio Palumbo, Paolo Corradini, Michele Cavo, Michel Delforge, Katja C. Weisel, Enrique M. Ocio, MD PhD, Francesco Di Raimondo, Markus Hansson, Mathew Simcock, Neil Miller, Ana Slaughter, Teresa Peluso, Lars Sternas, Mohamed H Zaki, Philippe Moreau

Blood (2015) 126 (23): 4225.

https://doi.org/10.1182/blood.V126.23.4225.4225

Published: 2015

Journal Articles

Bortezomib Plus Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) in Newly Diagnosed Elderly Myeloma Patients Overcome the Poor Prognosis of High-Risk Cytogenetic Abnormalities (CA) Detected By Fluorescence in Situ Hibridization (FISH)

Blood (2015) 126 (23): 4243.

https://doi.org/10.1182/blood.V126.23.4243.4243

Published: 2015

Journal Articles

Analysis of Patient (Pt) Outcomes By Prior Treatment and Depth of Response in Stratus (MM-010), a Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2015) 126 (23): 1834.

https://doi.org/10.1182/blood.V126.23.1834.1834

Published: 2015

Journal Articles

The Hybrid Molecule, Edo-S101, Impairs Double Strand Breaks Repair in Multiple Myeloma and Synergizes with Bortezomib and Dexamethasone

Ana Alicia López-Iglesias, Ana Belen Herrero, Laura San-Segundo, Susana Hernández-García, Lorena González-Méndez, Montserrat Martín-Sánchez, Esperanza M Algarín, Teresa Paino, Mercedes Garayoa, Thomas Mehrling, MD PhD, Norma C Gutierrez, Jesús F. San-Miguel, MD, Maria-Victoria Mateos, Enrique M. Ocio, MD PhD

Blood (2015) 126 (23): 5354.

https://doi.org/10.1182/blood.V126.23.5354.5354

Published: 2015

Journal Articles

A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma

Blood (2015) 126 (23): 509.

https://doi.org/10.1182/blood.V126.23.509.509

Published: 2015

Journal Articles

Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023

Jesus San Miguel, MD PhD, Maria-Victoria Mateos, MD PhD, Jatin J. Shah, MD, Enrique M. Ocio, MD PhD, Paula Rodriguez-Otero, MD PhD, Donna Reece, MD, Nikhil C. Munshi, MD, David Avigan, MD, Yang Ge, PhD, Arun Balakumaran, MD PhD SM, Patricia Marinello, PharmD, Robert Z. Orlowski, MD PhD, David Siegel, MD PhD

Blood (2015) 126 (23): 505.

https://doi.org/10.1182/blood.V126.23.505.505

Published: 2015

Journal Articles

The Alkylating Histone Deacetylase Inhibitor Fusion Molecule Edo-S101 Displays Full Bi-Functional Properties in Preclinical Models of Hematological Malignancies

Ana Alicia López-Iglesias, MD, Laura San-Segundo, Lorena González-Méndez, Susana Hernández-García, Daniel Primo, PhD, Mercedes Garayoa, PhD BS, Ana Belén Hernández, PhD, Teresa Paíno, PhD, Maria-Victoria Mateos, MD PhD, Yi Chen, Enrique M. Ocio, MD PhD, Thomas Mehrling, MD PhD

Blood (2014) 124 (21): 2100.

https://doi.org/10.1182/blood.V124.21.2100.2100

Published: 2014

Journal Articles

Bence Jones Proteinuria in Smoldering Multiple Myeloma As Predictor Marker of Progression to Symptomatic Multiple Myeloma

Veronica Gonzalez de la Calle, MD, Ramon Garcia-Sanz, Eduardo Sobejano, Enrique M. Ocio, MD PhD, Noemi Puig, MD PhD, Norma Carmen Gutierrez, PhD MD, Alberto Melón, MD, Joaquin Gonzalez, MD, Alfonso Garcia de Coca, MD, Jose M. Hernandez, MD, Roberto Hernandez, MD, Abelardo Barez, MDPhD, Jose M. Alonso, MD, Carmen Aguilera, MD, Fernando Escalante, Guillermo Martin, MD, Rosa Lopez, MD, Pilar de la Fuente, MD, Maria-Victoria Mateos, MD PhD

Blood (2014) 124 (21): 3369.

https://doi.org/10.1182/blood.V124.21.3369.3369

Published: 2014

Journal Articles

Clinical Significance of Sensitive Flow-MRD Monitoring in Elderly Multiple Myeloma Patients on the Pethema/GEM2010MAS65 Trial

Blood (2014) 124 (21): 3390.

https://doi.org/10.1182/blood.V124.21.3390.3390

Published: 2014

Journal Articles

Defining the Differentiation Stage of Multiple Myeloma Plasma Cells: Biological and Clinical Significance

Blood (2014) 124 (21): 25.

https://doi.org/10.1182/blood.V124.21.25.25

Published: 2014

Journal Articles

Safety and Efficacy in the Stratus (MM-010) Trial, a Single-Arm Phase 3b Study Evaluating Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma

Meletios A. Dimopoulos, MD, Antonio Palumbo, MD, Katja Weisel, MD, Enrique M. Ocio, MD PhD, Michele Cavo, MD, Paolo Corradini, MD PhD, Michel Delforge, MD PhF, Albert Oriol, MD, Hartmut Goldschmidt, MD, María Jesús Blanchard, MD, Chantal Doyen, MD, Gareth J Morgan, MD PhD, Mathew Simcock, MSc, Neil Miller, CRS, Ana Slaughter, PhD, Teresa Peluso, MBBS, Lars Sternas, MD, Mohamed H. Zaki, MD PhD, Philippe Moreau, MD

Blood (2014) 124 (21): 80.

https://doi.org/10.1182/blood.V124.21.80.80

Published: 2014

NARROW

Risk Adapted Antifungal Strategy in Allogeneic Stem Cell Transplantation. Should We Change the Current Guidelines?

The Poor Prognosis of High Cytogenetics Abnormalities in Elderly Patients Might be Overcome with an Optimized Total Therapy Approach Including Proteasome Inhibitors, Imid's Compounds and Alkylators

Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

Safety and Efficacy of Filanesib in Combination with Pomalidomide and Dexamethasone in Refractory MM Patients. Phase Ib/II Pomdefil Clinical Trial Conducted By the Spanish MM Group

Ultra-Deep Targeted Sequencing Does Not Identify MM Patients with Different Prognosis: Results from a Randomized Phase II Clinical Trial

Whole-Exome Sequencing of Waldenström Macroglobulinemia Transformation into Aggressive Lymphoma

Prognostic Value of Immune Profiling Multiple Myeloma Patients during Minimal Residual Disease Monitoring in the Pethema/GEM2010MAS65 Study

Comparison Between First-Generation 4-Color Vs. Second-Generation 8-Color Multiparameter Flow Cytometry (MFC) to Monitor Minimal Residual Disease (MRD) in Multiple Myeloma (MM)

The Relevance of Minimal Residual Disease (MRD) Monitoring in Elderly Multiple Myeloma (MM) Patients

An Updated Analysis of the Stratus Trial (MM-010): Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Bortezomib Plus Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) in Newly Diagnosed Elderly Myeloma Patients Overcome the Poor Prognosis of High-Risk Cytogenetic Abnormalities (CA) Detected By Fluorescence in Situ Hibridization (FISH)

Analysis of Patient (Pt) Outcomes By Prior Treatment and Depth of Response in Stratus (MM-010), a Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

The Hybrid Molecule, Edo-S101, Impairs Double Strand Breaks Repair in Multiple Myeloma and Synergizes with Bortezomib and Dexamethasone

A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma

Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023

The Alkylating Histone Deacetylase Inhibitor Fusion Molecule Edo-S101 Displays Full Bi-Functional Properties in Preclinical Models of Hematological Malignancies

Bence Jones Proteinuria in Smoldering Multiple Myeloma As Predictor Marker of Progression to Symptomatic Multiple Myeloma

Clinical Significance of Sensitive Flow-MRD Monitoring in Elderly Multiple Myeloma Patients on the Pethema/GEM2010MAS65 Trial

Defining the Differentiation Stage of Multiple Myeloma Plasma Cells: Biological and Clinical Significance

Safety and Efficacy in the Stratus (MM-010) Trial, a Single-Arm Phase 3b Study Evaluating Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only